Postmortem distribution concentrations of the pain medication tapentadol and its metabolite N-desmethyltapentadol are reported. Tapentadol (Nucynta w ) is a synthetic mu-opioid receptor agonist that also has norepinephrine reuptake inhibitor action. The laboratory received two cases. Case 1: a 19-year-old, morbidly obese male with sudden unexpected death. Toxicology results revealed tapentadol (femoral blood: 0.77 mg/L, liver: 1.65 mg/kg), N-desmethyltapentadol (femoral blood: 0.07 mg/L, liver: 0.19 mg/kg), diazepam (femoral blood: 0.04 mg/L), nordiazepam (femoral blood: 0.06 mg/L) and amiodarone (femoral blood: 5.30 mg/L). Case 2: a 60-year-old female who died from complications following hip replacement. Only tapentadol (femoral blood: 0.26 mg/L, liver: 0.52 mg/kg) was found in the toxicology results. Quantitative results of tapentadol/N-desmethyltapentadol were achieved using liquid chromatography-tandem mass spectrometry in multiple reactions monitoring mode. This is the first known distribution study of tapentadol and N-desmethyltapentadol values in postmortem cases.
Introduction
Tapentadol (Nucynta w ) is a synthetic mu-opioid receptor agonist that also has norepinephrine reuptake inhibitor action. Respiratory depression is a risk of mu-opioid receptor agonists, even at moderate doses. This risk can be increased in patients with severe obesity, chronic obstructive pulmonary disease and sleep apnea, among others (1) . Tapentadol was approved by the Food and Drug Administration in 2008 and classified as a Schedule II controlled substance in 2009. Tapentadol is extensively metabolized primarily through phase 2 conjugation. Approximately 70% of the dose is excreted in the urine as tapentadol glucuronide or tapentadol sulfate, while neither contribute to the analgesic activity (2) . A total of 3% of the drug is excreted unchanged in the urine (2) . Many methods have been published for tapentadol (3, 4) but few describe postmortem toxicology (5, 6, 7) .
Case History

Case 1
A 19-year-old male with a history of asthma, possible chronic obstructive pulmonary disease and obstructive sleep apnea was found unresponsive and transported to hospital while receiving CPR. The decedent was 5'5", weighed 436.5 lbs, had a body mass index of 72.6 and had no known ethanol or illicit drug history. An autopsy was performed by the Office of the Chief Medical Examiner and the cause of death was listed as pending further investigation. Standard toxicological specimens were submitted for testing by the toxicology laboratory.
The following tests were completed for the detection of drugs in the subject's femoral blood: volatiles, immunoassay [Orasure, Bethlehem, PA: amphetamines, barbiturates, benzodiazepines, cocaine, methadone, phencyclidine (PCP), opiates, methamphetamine, tetrahydrocannabinol (THC)], full scan gas chromatography-mass spectrometry with nitrogen phosphorus detection (GC -MS-NPD) base screen, and liquid chromatography-tandem mass spectrometry (LC -MS-MS) directed multiple reaction monitoring (MRM) screen (180 drugs). The immunoassay produced a positive benzodiazepine response, which was confirmed in both the base screen and with GC -MS quantitation. An unknown peak with no library match was also found in the base screen (m/z 58, 221, 107). Upon receiving these preliminary results and following discussions with the medical examiner, further interviews with the family revealed that the decedent "sometimes took a pill to energize self" from an unmarked pill bottle. Using collegial assistance it was determined that this peak was may be the compound tapentadol. The decedent had no pharmaceutical prescriptions for tapentadol or diazepam, but over the course of the previous month had received prescriptions for enoxaparin, albuterol, ipratropium, petrolat, ceftriaxone, pantoprazole, furosemide, gentamicin, advair, senna and Colace. Our laboratory would not expect to detect any of these drugs at therapeutic concentrations, with the exception of albuterol. None of these were detected. Tapentadol was confirmed by LC-MS-MS.
Case 2
A 69-year-old female with a history of chronic obstructive pulmonary disease, asthma, treated lung cancer, and coronary artery disease was admitted to the hospital for a hip replacement surgery due to osteoarthritis. The decedent was 5'7", weighed 287.5 lbs, and had a body mass index of 44.9, with no known ethanol or illicit drug history. The day following the surgery, she began to have an altered mental status and respiratory distress. The decedent developed rhabdomyolysis, acute tubular necrosis and atrial fibrillation, requiring a higher level of care. She died eight days later from complications of hip replacement surgery. An autopsy was performed by the Office of the Chief Medical Examiner and the cause of death was listed as pending further investigation. Standard toxicological specimens were retained for further testing by the toxicology laboratory.
The following tests were completed for the detection of drugs in the subject's femoral blood: volatiles, immunoassay (Orasure, Bethlehem, PA: amphetamines, barbiturates, benzodiazepines, cocaine, methadone, PCP, opiates, methamphetamine, THC) and a full scan GC -MS-NPD base screen. The base screen was positive for tapentadol and confirmed by LC -MS-MS.
Experimental
Reagents and materials Acetonitrile, methanol, methylene chloride, isopropanol, hydrochloric acid, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate, potassium hydroxide, ammonium hydroxide, ammonium formate and formic acid were all purchased from Fisher Scientific (Pittsburgh, PA). All organic solvents were high-performance liquid chromatography (HPLC) grade. Clean screen w (CSDAU) solid-phase extraction columns were obtained from United Chemical Technology (Bristol, PA). 
Standards, calibrators and control preparations
Sample preparation and method validation
An aliquot of 1 mL of liquid specimen or 1 g of tissue (homogenized at 1:4 dilution) was removed and spiked with 0.25 mg/L of internal standard (tapentadol-d 3 ). Potassium phosphate buffer (1.0 mL, 0.3 M, pH 6.0) was added to each sample and mixed. Urine samples were hydrolyzed with 300 mL of concentrated HCl and heated at 958C for 40 min. Samples were cooled, 275 mL concentrated KOH and 1 mL potassium phosphate buffer were added and then the samples' pH was adjusted to 6.
Solid-phase columns were conditioned with 2 mL methanol, 2 mL deionized water and 1 mL of potassium phosphate buffer. The samples were added to conditioned columns. The columns were washed with 3 mL deionized water, 2 mL 0.1 M hydrochloric acid and 3 mL methanol. The columns were then dried for 5 min. Samples were eluded using a solvent (2 mL, 78:20:2 v/v methylene chloride-isopropanol-ammonium hydroxide) and 25 mL of 1% methanolic HCL was added before drying down under a stream of nitrogen. The samples were reconstituted in 100 uL of 5 mM ammonium formate ( pH 3) -acetonitrile (80:20, v/v).
Instrumentation
An Acquity ultra-performance liquid chromatograph-tandem quadrupole detector (UPLC-TQD) operating in positive ESI mode was used for analysis (Waters, Milford, MA). Chromatographic separation was performed on a Waters Acquity UPLC HSS C18 column (2.1 Â 150 mm Â 1.8 mM) held at 508C, with an injection volume of 6 mL. The mobile phase was set at a flow rate of 0.4 mL/min and consisted of 5 mM (pH 3.0) ammonium formate (A) and acetonitrile (B). The gradient elution was set at an initial level of 80% A-20% B for 30 s. Over 4.0 min, the percentage of B was increased to 80%. The concentration was returned to a level of 80% A-20% B for 1 min. The source temperature was 1508C and desolvation (nitrogen) flow rate set at 800 L/h and 4008C. The collision gas (argon) was set at a flow rate of 0.10 mL/min. The transition ions, cone energy and collision energy are shown in Table I .
Results
Method validation
The UPLC-MS-MS method for tapentadol and N-desmethyltapentadol quanitation was validated in blood and urine using the conditions previously stated (Table II) . The following parameters were measured for the validation in blood: selectivity, specificity, linearity, limit of quantitation, upper limit of linearity, precision and accuracy. Selectivity was evaluated by extracting multiple sources of negative blood and urine matrices. There was no interference with the analysis at the retention time of the analytes. Specificity was evaluated by analyzing positive samples that contained 44 commonly encountered compounds (spiked at 5 mg/L) for possible interference with the assay. Linearity was determined by the analysis of a calibration curve (six points) on multiple days with a minimum linear regression of 0.992. The data were fit to a linear curve with a 1/x weighting and not forced through the origin. The limit of quantitation (LOQ) was determined to be 0.05 mg/L and the upper limit of quantitation (ULOQ) was 1.0 mg/L. These were determined by spiking samples (n ¼ 5) at both concentrations and meeting all criteria for confirmation, including the calculated concentration being within +20% of theoretical. Between-day precision was measured by the analysis of one sample at three different control concentrations over the course of ten extractions. Within-day precision was determined by the analysis of five samples at three different control concentrations in one extraction.
Stability
Tapentadol and N-desmethyltapentadol were spiked (0.8 mg/L) into certified negative blood and certified negative urine. These samples were then divided, stored at room temperature, 48C and -208C. A set of three samples was extracted on the day of spiking to obtain an initial value. A set of blood and urine specimens at the varying temperature storage conditions were then extracted on Day 1, 7, 21, 27 and 182. Tapentadol was stable over the full time period in both matrixes in all temperatures. N-desmethyltapentadol was stable over the full time period in both matrixes when stored at 48C and -208C. N-desmethyltapentadol had a 21% loss in blood at Day 27 and 95% loss by Day 182 at room temperature storage.
Case results
Case 1
The cause of death was subsequently amended to mixed drug toxicity with contributory condition obesity; dilated cardiomyopathy, and the manner of death was determined to be accidental. The tapentadol blood ranges were in range of previously reported deaths (6) , and tapentadol in combination with diazepam was thought to result in respiratory compromise resulting in death. Table III contains the tissue distribution for tapentadol and N-desmethyltapentadol in the specimens received, as well as other drugs found. It is believed that the amiodarone was given as part of the resuscitation procedure while being transported to the hospital. Amiodarone is an antiarrhythmic agent used for irregular heartbeats. The blood and liver concentrations of amiodarone were found to be within therapeutic doses (7).
Case 2
The cause of death was subsequently amended to complications following total hip replacement for the treatment of osteoarthritis with contributory causes of hypertensive and atherosclerotic cardiovascular disease, morbid obesity, atrial fibrillation and chronic obstructive pulmonary disease. The manner of death was determined to be natural. Table IV contains the tissue distribution for tapentadol and N-desmethyltapentadol in the specimens received.
Discussion
In Case 1, neither tapentadol nor diazepam were medications that were prescribed to the decedent, according to discussions with family and a review of medical records. Initially, given the mechanism of norepinephrine reuptake from tapentadol and the dilated cardiomyopathy found at autopsy, the mechanism of death was thought to be cardiac in origin. However, given the decedent's history of respiratory compromise from the obesity, obstructive sleep apnea and asthma, the drugs found in his system would complicate his ability to respire. Therefore, the mechanism of death in this case was the respiratory depression. In Case 2, the decedent was being monitored and went into asystole/cardiopulmonary arrest, secondary to hypovolemic shock from a retroperitoneal bleed (a complication of the surgery). Before coding, hypotension and bradycardia were clinically noted, a potential side effect of tapentadol. Based on the decedent being monitored by the hospital, it is difficult to ascertain tapentadol's contribution to death. This is the first known distribution of tapentadol and N-desmethyltapentadol values in postmortem tissues. This may be an example of toxic concentrations of tapentadol in Case 1 based on the medical history of the decedent and potentially therapeutic concentrations in Case 2. An increase in case studies involving this drug will assist medical examiners and toxicologists with interpreting postmortem concentrations. 
